Lupin names independent director
Lupin has a new director. The company announced the appointment of Christine Mundkur as an independent director.
Mundkur most recently served as CEO and non-voting chairman of the board of directors for Impopharma, a developer of complex formulations focused on inhalation pharmaceutical products.
While at Impopharma, she led the transition of the company from a successful clinical research organization into a generic pharmaceutical inhalation development company, Lupin said.
She also held leadership positions as president and CEO North America for Sandoz. Earlier, she served as CEO of Barr Laboratories.
Mundkur started her career at Barr as quality and regulatory counsel. In addition, she served as a strategic advisor to clients on generics, 505(b)2, biosimilars and NDA business strategies. She currently serves on the board of directors for MannKind in the U.S.
Mundkur most recently served as CEO and non-voting chairman of the board of directors for Impopharma, a developer of complex formulations focused on inhalation pharmaceutical products.
While at Impopharma, she led the transition of the company from a successful clinical research organization into a generic pharmaceutical inhalation development company, Lupin said.
She also held leadership positions as president and CEO North America for Sandoz. Earlier, she served as CEO of Barr Laboratories.
Mundkur started her career at Barr as quality and regulatory counsel. In addition, she served as a strategic advisor to clients on generics, 505(b)2, biosimilars and NDA business strategies. She currently serves on the board of directors for MannKind in the U.S.